• BridgeBio Pharma approved restricted stock units covering 147,578 common shares for 80 new employees on November 5, 2026.
• One-fourth of each award vests November 16, 2027; one-twelfth of the remaining shares vests quarterly thereafter.
• Vesting requires continued employment with the company or one of its subsidiaries on each vesting date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611061601PRIMZONEFULLFEED9872197) on November 06, 2026, and is solely responsible for the information contained therein.